» Articles » PMID: 27721325

Degradable Cross-Linked Nanoassemblies As Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin

Overview
Publisher MDPI
Specialty Chemistry
Date 2016 Oct 11
PMID 27721325
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Cross-linked nanoassemblies (CNAs) with a degradable core were prepared for sustained release of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), a potent inhibitor of heat shock protein 90 (HSP90). The particle size of CNAs ranged between 100 and 250 nm, which changed depending on the cross-linking yields and drug entrapment method. CNAs with a 1% cross-linking yield entrapped 17-AAG in aqueous solutions, yet degraded in 3 hrs. CNAs entrapped 5.2 weight% of 17-AAG as the cross-linking yield increased to 10%, retaining more than 80% of particles for 24 hrs. CNAs with drugs entrapped after the cross-linking reactions were 100 nm and remained stable in both pH 7.4 and 5.0, corresponding to the physiological, tumoral, and intracellular environments. Drug was completely released from CNAs in 48 hrs, which would potentially maximize drug delivery and release efficiency within tumor tissues. Drug release patterns were not negatively affected by changing the cross-linking yields of CNAs. CNAs entrapping 17-AAG suppressed the growth of human non-small cell lung cancer A549 cells as equally effective as free drugs. The results demonstrated that CNAs would be a promising formulation that can be used in aqueous solutions for controlled delivery and release of 17-AAG.

Citing Articles

Comparison of Dialysis- and Solvatofluorochromism-Based Methods to Determine Drug Release Rates from Polymer Nanoassemblies.

Reichel D, Bae Y Pharm Res. 2016; 34(2):394-407.

PMID: 27873146 DOI: 10.1007/s11095-016-2070-6.


Block copolymer cross-linked nanoassemblies improve particle stability and biocompatibility of superparamagnetic iron oxide nanoparticles.

Dan M, Scott D, Hardy P, Wydra R, Hilt J, Yokel R Pharm Res. 2012; 30(2):552-61.

PMID: 23080062 PMC: 4076800. DOI: 10.1007/s11095-012-0900-8.

References
1.
Olson P, Lu J, Zhang H, Shai A, Chun M, Wang Y . MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009; 23(18):2152-65. PMC: 2751988. DOI: 10.1101/gad.1820109. View

2.
Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2010; 63(3):131-5. DOI: 10.1016/j.addr.2010.03.011. View

3.
Kano M, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M . Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A. 2007; 104(9):3460-5. PMC: 1800736. DOI: 10.1073/pnas.0611660104. View

4.
Ponta A, Bae Y . PEG-poly(amino acid) block copolymer micelles for tunable drug release. Pharm Res. 2010; 27(11):2330-42. DOI: 10.1007/s11095-010-0120-z. View

5.
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M, Fritz L . A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003; 425(6956):407-10. DOI: 10.1038/nature01913. View